CareDx, Inc. CDNA R2KR3KPHARMA
Company Overview
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Why Investors Should Care
Generates a return on equity of 29.5%, reflecting efficient use of shareholder capital.
Revenue has grown at a 25.2% CAGR over the past five years.
Trades at a P/E of 24.5, below the sector median of 25.2.
Maintains a net profit margin of 24.2%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $379.81M (+13.8% YoY); net profit $-21.35M.
- Trailing 12 Months Year-on-year growth — revenue +52.2%, earnings -140.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 25.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.20% |
| 1 Year: | 52.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -140.64% |
Stock Price Performance
| 1 Year: | +319.46% |
| 6 Months: | +184.40% |
| 3 Months: | +128.67% |
| 1 Month: | +13.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.49 · Neutral
P/E of 24.46 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 29.5%.
- Excellent profit margin of 24.2%.
- Compounding revenue at 25.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CDNA CareDx, Inc. R2KR3KPHARMA | 50.88 | 24.46 | $2.63B | 0.00% | -9.52% | 29.49% | 25.20% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 11.58M | 12.05M | 12.19M | 12.50M | 14.05M | 17.82M | 21.18M | 23.51M | 25.98M | 31.45M | 33.81M | 35.82M | 38.38M | 41.80M | 53.37M | 67.40M | 74.19M | 75.59M | 79.42M | 80.63M | 79.36M | 77.26M | 70.30M | 67.19M | 72.05M | 92.27M | 82.88M | 84.69M | 86.68M | 100.06M | 117.70M | 131.95M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.62M | 12.30M | - | 16.25M | 19.94M | 22.32M | - | 25.99M | 26.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.39M | -2.89M | -3.19M | - | -6.57M | -6.97M | -4.93M | - | -8.54M | -3.60M | -3.86M | - | -5.24M | -5.21M | -2.72M | - | -5.40M | -6.84M | -6.75M | - | -5.75M | -10.80M | -2.91M | -858.00K | -4.74M | -8.73M | -19.05M | -21.72M | -17.34M | -24.32M | -27.62M | -28.78M | -22.57M | -7.33M | -13.72M | -13.37M | -11.12M | -246.00K | 1.20M | 113.22M |
| Net Income | -2.27M | -3.19M | -3.49M | -4.76M | -9.75M | -10.47M | -3.76M | -15.48M | -5.56M | -3.97M | -14.27M | -31.67M | -8.97M | -14.06M | -19.97M | -3.75M | -7.53M | -7.85M | -1.81M | -4.78M | -5.82M | -6.56M | -2.82M | -687.00K | -1.93M | -11.90M | -19.65M | -21.70M | -16.94M | -23.75M | -24.95M | -23.48M | -19.89M | -4.62M | -10.64M | -10.35M | -8.57M | 1.68M | 2.81M | 110.64M |
| Diluted EPS | -0.19 | -0.27 | -0.29 | -0.40 | -0.81 | -0.77 | -0.26 | -0.73 | -0.26 | -0.19 | -0.63 | -1.13 | -0.30 | -0.40 | -0.54 | -0.09 | -0.18 | -0.19 | -0.04 | -0.11 | -0.14 | -0.15 | -0.06 | -0.01 | -0.04 | -0.23 | -0.37 | -0.41 | -0.32 | -0.44 | -0.46 | -0.43 | -0.38 | -0.09 | -0.20 | -0.19 | -0.16 | 0.03 | 0.05 | 2.07 |
| R&D Expense | 1.42M | 2.51M | 2.70M | - | 3.16M | 3.14M | 2.93M | - | 3.28M | 3.12M | 2.96M | - | 3.37M | 3.50M | 3.87M | - | 5.61M | 7.63M | 8.52M | - | 10.01M | 13.13M | 12.47M | 16.00M | 19.04M | 19.44M | 21.88M | 22.63M | 22.31M | 24.36M | 20.23M | 19.00M | 18.71M | 19.69M | 17.49M | 18.52M | 16.83M | 16.77M | 21.42M | 22.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.45M | 22.10M | 27.31M | 28.14M | 40.63M | 48.32M | 76.57M | 127.07M | 192.19M | 296.40M | 321.79M | 280.32M | 333.79M | 379.81M |
| Gross Profit | - | - | - | - | - | 26.95M | 43.58M | 81.61M | - | - | - | - | - | - |
| Operating Income | -2.34M | -857.00K | 1.25M | -11.93M | -37.33M | -20.29M | -15.58M | -24.53M | -22.53M | -29.73M | -77.23M | -203.36M | 40.77M | -30.78M |
| Net Income | -5.06M | -3.54M | 781.00K | -13.71M | -39.47M | -55.47M | -46.76M | -21.97M | -18.71M | -30.66M | -76.61M | -190.28M | 52.55M | -21.35M |
| Diluted EPS | -5.01 | -3.50 | 0.10 | -1.16 | -2.39 | -2.38 | -1.31 | -0.52 | -0.40 | -0.59 | -1.44 | -3.54 | 0.93 | -0.40 |
| R&D Expense | 4.75M | 3.18M | 3.85M | 9.33M | 12.38M | 12.39M | 14.51M | 30.71M | 48.94M | 76.53M | 90.39M | 82.42M | 72.51M | 71.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 9.87M | 61.14M | 63.28M | 61.37M | 59.34M | 55.64M | 48.83M | 100.45M | 102.09M | 76.73M | 80.32M | 77.74M | 75.09M | 83.56M | 130.70M | 151.74M | 368.51M | 566.62M | 542.99M | 466.83M | 491.05M | 413.23M |
| Total Equity | -142.22M | -147.20M | -150.67M | 41.30M | - | - | - | 29.49M | - | - | - | 19.48M | - | - | - | -6.13M | 95.93M | 99.00M | 277.68M | 465.88M | 430.91M | 261.33M | 378.43M | 303.10M |
| Cash & Equivalents | 2.36M | 5.83M | 5.13M | 36.43M | - | - | - | 29.89M | - | - | - | 17.26M | - | - | - | 16.89M | 64.62M | 38.22M | 134.67M | 348.49M | 89.92M | 82.20M | 114.69M | 65.43M |
| Long Term Debt | - | - | 10.91M | 5.45M | 14.61M | 13.39M | 12.12M | 12.89M | 11.37M | 10.07M | 8.50M | 1.10M | 0 | 0 | 21.17M | 18.34M | 0 | 0 | 0 | - | - | - | - | - |
| Total Liabilities | - | - | 25.34M | 19.84M | - | - | - | 26.14M | - | - | - | 56.97M | - | - | - | 89.52M | 34.77M | 52.74M | 90.83M | 100.75M | 112.08M | 205.50M | 112.62M | 110.13M |
| Current Liabilities | - | - | 7.59M | 11.13M | - | - | - | 10.15M | - | - | - | 40.83M | - | - | - | 42.91M | 19.50M | 34.83M | 69.22M | 77.30M | 75.97M | 78.07M | 89.37M | 89.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -16.52M | -14.31M | -4.01M | -2.77M | 33.43M | -19.29M | -25.24M | -18.39M | 38.05M | 42.03M |
| Investing Cash Flow | - | - | - | - | -21.12M | -6.11M | -7.93M | -22.58M | -100.39M | 47.71M | -228.50M | 40.45M | -483.00K | 2.16M |
| Financing Cash Flow | - | - | - | - | 24.93M | 29.38M | 50.27M | -132.00K | 163.15M | 185.64M | -4.54M | -29.61M | -5.61M | -93.39M |
| Capital Expenditure | -141.00K | -98.00K | -733.00K | -1.20M | -549.00K | -186.00K | -2.04M | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | -17.07M | -14.49M | -6.04M | - | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 0 | 642.00K | 27.54M | 522.00K | 87.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 55.8% | 56.9% | 64.2% | - | - | - | - | - | - |
| Operating Margin % | -11.5% | -3.9% | 4.6% | -42.4% | -91.9% | -42.0% | -20.3% | -19.3% | -11.7% | -10.0% | -24.0% | -72.5% | 12.2% | -8.1% |
| Net Margin % | -24.7% | -16.0% | 2.9% | -48.7% | -97.1% | -114.8% | -61.1% | -17.3% | -9.7% | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
| ROE % | 3.4% | 2.4% | 1.9% | -46.5% | -202.6% | 904.3% | -48.7% | -22.2% | -6.7% | -6.6% | -17.8% | -72.8% | 13.9% | -7.0% |
| ROCE % | - | -37.6% | 2.5% | -26.2% | -104.0% | -49.9% | -14.0% | -21.0% | -7.5% | -6.1% | -16.5% | -52.3% | 10.1% | -9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.31% | 4.81M | $239.72M |
| 2 | State Street Corporation | 4.77% | 2.47M | $122.92M |
| 3 | Vanguard Capital Management LLC | 4.25% | 2.20M | $109.41M |
| 4 | Deerfield Management Company, L.P | 3.86% | 2.00M | $99.46M |
| 5 | ARK Investment Management, LLC | 3.78% | 1.95M | $97.27M |
| 6 | Boston Partners | 3.75% | 1.94M | $96.47M |
| 7 | BAMCO Inc. | 3.74% | 1.94M | $96.46M |
| 8 | Gagnon Securities, LLC | 3.42% | 1.77M | $88.16M |
| 9 | Chevy Chase Trust Holdings, LLC | 2.78% | 1.44M | $71.57M |
| 10 | Geode Capital Management, LLC | 2.57% | 1.33M | $66.12M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CDNA
CareDx (CDNA) Rallies On Transplant Growth Narrative But Is The Valuation Still Compelling - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNWnJUSzBmcEQwR2pyU0dGUVJPeEFIemtpSm9zNFc4S0trbHFYbGlaSG1OTVNOZ2VablR2VGI2Q1dMSG5rbjFxNERzbDdGWmdWQUNHejM4NlJVRjNPX0FRRDAyd1FjbElFdVZzeVJKTVhFWWctTG5fQXVJd2dFUXlrUGVDU2lQdGdGVXZDbD…
CareDx (CDNA) Shares Jumped, So What Is Driving Attention Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQcTdmRHh1X3R2Q2lYQnpWY1dKNUJSS1dndWUtSVBMbUV1Wm1aZGZpdHp2RHpVVVI1dGFTR2pIUXRwOXRTX2U4Y19HbTlTWlRvemxlQXZOZng1X0xZOXVnOHZmOUxld0U1LXB6ZklXclo3Rl9VQndSS3BNY3FQWDEtTGhBczFEYkliVVBWSn…
CareDx (NASDAQ: CDNA) insider lines up $423K stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOQThkZzh4d0JleVVFRGNUMGhfMHRQLTYtTVptUzZxc1ZqT1Uxblc1SDYwOU9iTjIwWlBhYTNqaFJud3ViTjZLODVJVHN3aXBxTE5KSFZoM1JSSmh3Z2JmM3FJNGJsNXhBdHdrT2x2WDZSa3BQeFBrMndJTEVDeE5ORlFTck96ODRJYWR2Tl…
Technical Reactions to CDNA Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNNUVUdVNKcHVjcVlZMUdEMlFyOXVVWmxtWXFRYzZnZ3dTNTFFOFQ1VElUZGhGcERDZEN2bWNHZTM3ZV9wbGRGSmd6Y081cHVhY3NBUzJ1V2VSNFFUd190emlVQmJoZklFVXVUMXU0QW5aRDNidC1yRjJkd2twcmxvV1B2QUNLZXRxZEdBS1…
CareDx (NASDAQ:CDNA) Beats Q1 Estimates and Raises Full-Year Guidance, But Stock Slips - ChartMill
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOYk1ReHVlZHIxVHRieUNzTmJabFhQX1g4LUwxNkRMY0JtMk1RLXNGUENxNmlQY0s5ZlJvY3k3WGhPQjM1UnEwOF9JOVVlLTBxQkpuNUhrMG1weXJocjRtMmhsaWYxb3dKd2FfeHdnMTRUb1VTUlpLcm1pRXk1bGF4UHhMaHVWZUF0Yi1WRF…
CareDx (CDNA) is a Great Momentum Stock: Should You Buy? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQRWhQMFBGUDlUNkkwdzY5Mlhkc20tZ3FPZ2c3Q1hVSXU5X2F0R2NvQzR1by1aS3ltWDFyeUg3QURINFVQdFc3QzFNaHB6R1hoMmwwdlF1UGpIcC1UVng1dkdOMlA3NllIdWRVNnZtc0FQVHlhUjFZcmpkUjFEZm1LajBJRk5iNVBoMVh0bn…
CDNA — Frequently Asked Questions
What is the current share price of CareDx, Inc. (CDNA)?
As of 2026-09-07 16:24 PDT, CareDx, Inc. (CDNA) trades at $50.88 on NasdaqGM. Its 52-week range is $11.57 to $52.36.
What is the market capitalisation of CDNA?
CareDx, Inc. (CDNA) has a market capitalisation of $2.63B on NasdaqGM.
What is the P/E ratio of CDNA?
CDNA trades at a trailing price-to-earnings (P/E) ratio of 24.46. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.65.
What is the return on equity (ROE) of CDNA?
CDNA has a return on equity (ROE) of 29.49%. Its return on capital employed (ROCE) is -9.52%.
Is CDNA a good stock to buy?
This page provides a data-driven analysis of CareDx, Inc. (CDNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.